Repay Holdings Reports Q1 Results, Details KUBRA Acquisition Financing, and Addresses Activist Pressure with Poison Pill

summarizeSummary

Repay Holdings reported Q1 2026 results with modest revenue and Adjusted EBITDA growth but increased net loss, while detailing the financing for its major KUBRA acquisition and addressing activist pressure with a new poison pill.

check_boxKey Events

• Q1 2026 Financial Performance

  Revenue increased 4.5% year-over-year to $80.8 million, and Adjusted EBITDA grew 3.6% to $34.4 million, confirming preliminary figures. However, net loss attributable to the company increased by 25.2% to $9.9 million.

• Significant Cash Reduction and Debt Restructuring

  Cash and cash equivalents decreased from $115.7 million to $43.8 million in Q1 2026. This was primarily due to the repayment of $146.5 million in 2026 Notes, partially offset by a $110 million draw from the revolving credit facility, leading to an increase in long-term debt to $390.6 million.

• KUBRA Acquisition Financing Detailed

  The company provided further details on the March 30, 2026, agreement to acquire KUBRA for approximately $372 million. The acquisition is expected to be financed through a combination of cash on hand and proposed new debt facilities, including a $500 million term loan and a $100 million revolving credit facility.

• Stockholder Rights Plan Adopted

  On April 13, 2026, the Board of Directors adopted a stockholder rights plan (poison pill) with a 12.5% triggering threshold, a defensive measure explicitly linked to activist stockholder actions.

auto_awesomeAnalysis

This 10-Q provides the definitive Q1 2026 financial results, confirming modest revenue and Adjusted EBITDA growth but also a significant increase in net loss and a substantial reduction in cash reserves due to debt repayments. The filing offers comprehensive details on the transformational KUBRA acquisition, a $372 million deal that will significantly increase the company's debt load. Furthermore, the company's explicit acknowledgment of activist stockholder impact and the adoption of a defensive stockholder rights plan (poison pill) highlight ongoing corporate governance challenges. Investors should closely monitor the integration of KUBRA, the company's leverage, and the evolving activist situation.